Intradermal hpv peptide vaccination

Abstract

The invention relates to the use of a peptide derived from HPV-E2, -E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for interdermal administration.

1 . A method for treatment of an HPV-induced intraepithelial neoplasia or cancer selected from a Human Papilloma Virus (HPV) infection, an HPV associated malignancy, a Cervical Intra-epithelial Neoplasia (CIN), a vulva Intra-epithelial Neoplasia (VIN), an Anal Intra-epithelial Neoplasia (AIN), a Vaginal Intra-epithelial Neoplasia (VAIN), a Penile Intra-epithelial Neoplasia (PIN), a cervical cancer, a vulva cancer, an anal cancer, a vaginal cancer, a head and neck cancer or a penile cancer, in a human in need thereof, the method comprising administering intradermally to the human a composition comprising a pool of the following peptides:
 (i) a peptide comprising SEQ ID NO: 7 and a peptide comprising SEQ ID NO: 8;   (ii) a peptide comprising SEQ ID NO: 9 and a peptide comprising SEQ ID NO: 10;   (iii) a peptide comprising SEQ ID NO: 11 and a peptide comprising SEQ ID NO: 12;   (iv) a peptide comprising SEQ ID NO: 13, a peptide comprising SEQ ID NO: 14, and a peptide comprising SEQ ID NO: 15;   (v) a peptide comprising SEQ ID NO: 16 and a peptide comprising SEQ ID NO: 17;   (vi) a peptide comprising SEQ ID NO: 18 and a peptide comprising SEQ ID NO: 19;   (vii) a peptide comprising SEQ ID NO: 20 and a peptide comprising SEQ ID NO: 21; and/or,   (vii) a combination thereof,
 wherein the peptides are of 22-45 contiguous amino acids of HPV-E2, -E6 or -E7 proteins and are administered in an amount suitable to elicit an antigen specific systemic cellular immune response with respect to the peptides, wherein the composition does not comprise a pharmaceutically acceptable adjuvant that has a depot function, and wherein the administering treats the HPV-induced intraepithelial neoplasia or cancer. 
   
     
     
         2 . The method according to  claim 1 , wherein the peptides are of 22-40, 22-35, 22, 25, 28, 32 or 35 amino acids in length. 
     
     
         3 . The method according to  claim 1 , wherein the composition further comprises a contiguous amino acid sequence from HPV-E7 protein. 
     
     
         4 . The method according to  claim 1 , wherein the composition is an aqueous solution. 
     
     
         5 . The method according to  claim 3 , wherein the contiguous amino acid sequence from the HPV-E7 protein comprises any one of SEQ ID NOS: 20-23. 
     
     
         6 . The method according to  claim 1 , wherein the composition is not formulated as an oil-water based emulsion. 
     
     
         7 . The method according to  claim 6 , wherein the composition is not formulated as a water-in-oil emulsion. 
     
     
         8 . The method according to  claim 1 , wherein the composition consists of a pool of peptides as defined in  claim 1 , optionally further peptides selected from the group comprising SEQ ID NO: 7-23, and an inert pharmaceutically acceptable carrier. 
     
     
         9 . The method according to  claim 1 , wherein the composition comprises a TLR ligand. 
     
     
         10 . The method according to  claim 9 , wherein the TLR ligand is a TLR 3, 4, 7, 8 and/or 9 ligand. 
     
     
         11 . The method according to  claim 1 , wherein the composition is intradermally administered directly at the site of the lesion. 
     
     
         12 . The method according to  claim 1 , further comprising a second composition comprising a peptide derived from HPV-E2, -E6 and/or -E7 protein, wherein the second composition is administered subcutaneously. 
     
     
         13 . The method according to  claim 1 , wherein the antigen specific systemic immune response comprises circulation of antigen specific T cells through the secondary lymph system of the subject. 
     
     
         14 . The method according to  claim 1 , wherein the antigen specific systemic immune response comprises circulation of antigen specific T cells in the peripheral blood of the subject. 
     
     
         15 . The method according to  claim 1 , wherein the composition comprises an additional peptide comprising any of the sequences of SEQ ID NO: 7-23. 
     
     
         16 . The method according to  claim 15 , wherein the composition is an aqueous solution. 
     
     
         17 . The method according to  claim 3 , wherein the composition is an aqueous solution. 
     
     
         18 . The method according to  claim 1 , wherein the composition comprises contiguous amino acid sequences from each of HPV-E2, -E6 and -E7 proteins. 
     
     
         19 . The method according to  claim 1 , for treatment of an HPV-induced intraepithelial neoplasia or cancer selected from, a Cervical Intra-epithelial Neoplasia (CIN), a vulva Intra-epithelial Neoplasia (VIN), an Anal Intra-epithelial Neoplasia (AIN), a cervical cancer, or a head and neck cancer. 
     
     
         20 . The method according to  claim 19 , for treatment of an HPV-induced intraepithelial neoplasia or cancer selected from a Cervical Intra-epithelial Neoplasia (CIN), a vulva Intra-epithelial Neoplasia (VIN) or an Anal Intra-epithelial Neoplasia (AIN).